Indication
For treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma.
Medicine details
- Medicine name:
- tebentafusp (Kimmtrak)
- SMC ID:
- SMC2910
- Pharmaceutical company
- Immunocore Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Publication due date:
- 13 July 2026
- SMC meeting date:
- 02 June 2026
- Patient group submission deadline:
- 05 May 2026